
药物靶标:受体相互作用蛋白激酶1(RIPK1) - 知乎专栏
ripk1蛋白包含三个部分:n-端激酶结构域、rip同型相互作用模块 (rhim)和c-端死亡结构域。 RIPK1具有的丝/苏氨酸激酶活性在程序性坏死、恢复体(ripoptosome)介导的半胱氨酸酶依赖 …
ROCK1 inhibition improves wound healing in diabetes via …
2024年3月27日 · Experiments using integrated bioinformatics analysis and coimmunoprecipitation established that ROCK1 inhibited pThr 172 -AMPKα by binding to receptor-interacting …
Nature拳头综述!袁钧瑛院士系统盘点RIPK1的生物学作用及药物 …
2020年7月20日 · 近日,美国科学院院士袁钧瑛团队在Nature Reviews Drug Discovery (IF=65)在线发表题为“Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic …
Targeting RIPK1 for the treatment of human diseases - PMC
RIPK1 kinase has emerged as a promising therapeutic target for the treatment of a wide range of human neurodegenerative, autoimmune, and inflammatory diseases. This was supported by …
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
2020年7月15日 · This article reviews RIPK1 biology and disease-associated mutations in RIPK1 signalling pathways, highlighting clinical trials of RIPK1 inhibitors and potential strategies to …
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic …
2020年8月20日 · Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key mediator of cell death and inflammation. The unique hydrophobic pocket in the allosteric regulatory …
靶向RIPK1、ROCK及SARS-CoV-2 Mpro特异性小分子抑制剂的设 …
本人在攻读博士学位期间,针对两种激酶,即ripk1和rock,开展了特异性抑制剂的设计、合成和构效关系研究,对活性和选择性最好的化合物,开展了药代动力学性质和安全性评价研究,并进 …
RIP-roaring inflammation: RIPK1 and RIPK3 driven NLRP3
The receptor-interacting protein kinases (RIPK) 1 and 3 are central to this network, as highlighted by the fact that mutations in genes encoding repressors of RIPK1 and/or RIPK3 activity can …
受体相互作用蛋白激酶1调节癌症进展和免疫反应的研究现状
This paper starts with the structure of RIPK1 to further explore its function in regulating cancer progression and immune response, and to provide new ideas for the development of cancer …
IF26!中科院最新成果,抑制蛋白激酶RIPK1能够延缓衰老
2024年4月22日 · 近日,中国科学院上海有机化学研究所生物与化学交叉研究中心许代超课题组在 Nature cell biology 期刊上发表了题为 Defective prelamin A processing promotes …